Maximizing Bioanalytical Efficiency: Multiplexed Quantitation of Free Payload, Intact Antibody-Drug Conjugate, and Total Antibody of Brentuximab Vedotin from a Single Rat Plasma Aliquot
Poster Authors:
Thomas Kralj, Vidya Sagar Pasumarty, Vijaya Karra, Mitesh Sanghvi
Pharmaron (Germantown) Lab Services Inc., Maryland, USA
Pharmacokinetic analysis of ADCs is more demanding than most small molecule work. Free payload, intact ADC, and total antibody endpoints must be quantified. Typically meaning three separate assays and three separate sample volumes. At WRIB 2026, Pharmaron scientist Thomas Kralj presented a methodology that consolidates all three into a single multiplexed quantitation program.
With 15 FDA-approved ADCs on the market and hundreds more in clinical development, running leaner and faster bioanalytical programs is crucial . This work offers a practical path forward.
Our Multiplexed Quantitation Method
The poster presents validation data for this multiplexed quantitation method development and validation in alignment with ICH M10 bioanalytical guidelines.
Capabilities
Poster highlights:
- LLOQ performance across all three endpoints
- Dilution linearity, matrix effect, and selectivity outcomes
- Complete LC-MS/MS conditions for free payload, intact ADC and total antibody
Download this Poster
Request the complete WRIB 2026 poster to review the validation tables, workflow diagram and LC-MS/MS conditions in detail. Pharmaron’s bioanalytical team is available to discuss how this method could be adapted for your ADC program.
References:
